BioCardia, Inc. (BCDA) Q4 2025 Earnings Call Transcript

SA Transcripts159.1K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call BioCardia, Inc. (BCDA) Q4 2025 Earnings Call March 24, 2026 4:30 PM EDT Company Participants Miranda Benvenuti - Investor Relations ExecutivePeter Altman - CEO, President & DirectorDavid McClung - Chief Financial Officer Conference Call Participants Lander Egaña-Gorroño - H.C. Wainwright & Co, LLC, Research DivisionJames Molloy - Alliance Global Partners, Research Division Presentation Operator Ladies and gentlemen, thank you for standing by. Good afternoon, and welcome to the BioCardia Year-end 2025 Financial Results and Business Update Conference Call. [Operator Instructions] Participants of this call are advised that the audio of this conference call is being broadcast live over the Internet and is also being recorded for playback purposes. A webcast replay of the call will be available approximately one hour after the end of the call. I would now like to turn the conference over to Miranda Peto of BioCardia Investor Relations. Please go ahead, Miranda. Miranda BenvenutiInvestor Relations Executive Good afternoon, and thank you for participating in today's conference call. Joining me from BioCardia's leadership team are Peter Altman, President and Chief Executive Officer; and David McClung, the company's Chief Financial Officer. During this call, management will be making forward-looking statements, including statements that address BioCardia's expectations for future performance and operational results, references to management's intentions, beliefs, projections, outlook, analyses and current expectations. Such factors include, among others, the inherent uncertainties associated with developing new products technologies and obtaining regulatory approvals. Forward-looking statements involve risks and other factors that may cause actual results to differ materially from those statements. For more information about these risks, please refer to the risk factors and cautionary statements described in Biocardia's reports on Form 10-K filed with the SEC today, March 24, 2026. The content of this call contains time-sensitive information that is accurate only as of today, March 24, 2026. Except